Effects of oxandrolone on outcome measures in the severely burned: A multicenter prospective randomized double-blind trial

Steven Wolf, Linda S. Edelman, Nathan Kemalyan, Lorraine Donison, James Cross, Marcia Underwood, Robert J. Spence, Dene Noppenberger, Tina L. Palmieri, David G. Greenhalgh, Marybeth Lawless, David Voigt, Paul Edwards, Petra Warner, Richard Kagan, Susan Hatfield, James Jeng, Daria Crean, John Hunt, Gary PurdueAgnes Burris, Bruce Cairns, Mary Kessler, Robert L. Klein, Rose Baker, Charles Yowler, Wendy Tutulo, Kevin Foster, Daniel Caruso, Brian Hildebrand, Wesley Benjamin, Cynthia Villarreal, Arthur P. Sanford, Jeffrey Saffle

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Severe burns induce pathophysiologic problems, among them catabolism of lean mass, leading to protracted hospitalization and prolonged recovery. Oxandrolone is an anabolic agent shown to decrease lean mass catabolism and improve wound healing in the severely burned patients. We enrolled 81 adult subjects with burns 20% to 60% TBSA in a multicenter trial testing the effects of oxandrolone on length of hospital stay. Subjects were randomized between oxandrolone 10 mg every 12 hours or placebo. The study was stopped halfway through projected enrollment because of a significant difference between groups found on planned interim analysis. We found that length of stay was shorter in the oxandrolone group (31.6 ± 3.1 days) than placebo (43.3 ± 5.3 days; P < .05). This difference strengthened when deaths were excluded and hospital stay was indexed to burn size (1.24 ± 0.15 days/% TBSA burned vs 0.87 ± 0.05 days/% TBSA burned, P < .05). We conclude that treatment using oxandrolone should be considered for use in the severely burned while hepatic transaminases are monitored.

Original languageEnglish (US)
Pages (from-to)131-139
Number of pages9
JournalJournal of Burn Care and Research
Volume27
Issue number2
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Oxandrolone
Outcome Assessment (Health Care)
Length of Stay
Burns
Placebos
Anabolic Agents
Transaminases
Wound Healing
Multicenter Studies
Hospitalization
Liver

ASJC Scopus subject areas

  • Surgery
  • Emergency Medicine
  • Rehabilitation

Cite this

Effects of oxandrolone on outcome measures in the severely burned : A multicenter prospective randomized double-blind trial. / Wolf, Steven; Edelman, Linda S.; Kemalyan, Nathan; Donison, Lorraine; Cross, James; Underwood, Marcia; Spence, Robert J.; Noppenberger, Dene; Palmieri, Tina L.; Greenhalgh, David G.; Lawless, Marybeth; Voigt, David; Edwards, Paul; Warner, Petra; Kagan, Richard; Hatfield, Susan; Jeng, James; Crean, Daria; Hunt, John; Purdue, Gary; Burris, Agnes; Cairns, Bruce; Kessler, Mary; Klein, Robert L.; Baker, Rose; Yowler, Charles; Tutulo, Wendy; Foster, Kevin; Caruso, Daniel; Hildebrand, Brian; Benjamin, Wesley; Villarreal, Cynthia; Sanford, Arthur P.; Saffle, Jeffrey.

In: Journal of Burn Care and Research, Vol. 27, No. 2, 01.03.2006, p. 131-139.

Research output: Contribution to journalArticle

Wolf, S, Edelman, LS, Kemalyan, N, Donison, L, Cross, J, Underwood, M, Spence, RJ, Noppenberger, D, Palmieri, TL, Greenhalgh, DG, Lawless, M, Voigt, D, Edwards, P, Warner, P, Kagan, R, Hatfield, S, Jeng, J, Crean, D, Hunt, J, Purdue, G, Burris, A, Cairns, B, Kessler, M, Klein, RL, Baker, R, Yowler, C, Tutulo, W, Foster, K, Caruso, D, Hildebrand, B, Benjamin, W, Villarreal, C, Sanford, AP & Saffle, J 2006, 'Effects of oxandrolone on outcome measures in the severely burned: A multicenter prospective randomized double-blind trial', Journal of Burn Care and Research, vol. 27, no. 2, pp. 131-139. https://doi.org/10.1097/01.BCR.0000202620.55751.4F
Wolf, Steven ; Edelman, Linda S. ; Kemalyan, Nathan ; Donison, Lorraine ; Cross, James ; Underwood, Marcia ; Spence, Robert J. ; Noppenberger, Dene ; Palmieri, Tina L. ; Greenhalgh, David G. ; Lawless, Marybeth ; Voigt, David ; Edwards, Paul ; Warner, Petra ; Kagan, Richard ; Hatfield, Susan ; Jeng, James ; Crean, Daria ; Hunt, John ; Purdue, Gary ; Burris, Agnes ; Cairns, Bruce ; Kessler, Mary ; Klein, Robert L. ; Baker, Rose ; Yowler, Charles ; Tutulo, Wendy ; Foster, Kevin ; Caruso, Daniel ; Hildebrand, Brian ; Benjamin, Wesley ; Villarreal, Cynthia ; Sanford, Arthur P. ; Saffle, Jeffrey. / Effects of oxandrolone on outcome measures in the severely burned : A multicenter prospective randomized double-blind trial. In: Journal of Burn Care and Research. 2006 ; Vol. 27, No. 2. pp. 131-139.
@article{8e769e033dde4c9b86d5ff0e91851080,
title = "Effects of oxandrolone on outcome measures in the severely burned: A multicenter prospective randomized double-blind trial",
abstract = "Severe burns induce pathophysiologic problems, among them catabolism of lean mass, leading to protracted hospitalization and prolonged recovery. Oxandrolone is an anabolic agent shown to decrease lean mass catabolism and improve wound healing in the severely burned patients. We enrolled 81 adult subjects with burns 20{\%} to 60{\%} TBSA in a multicenter trial testing the effects of oxandrolone on length of hospital stay. Subjects were randomized between oxandrolone 10 mg every 12 hours or placebo. The study was stopped halfway through projected enrollment because of a significant difference between groups found on planned interim analysis. We found that length of stay was shorter in the oxandrolone group (31.6 ± 3.1 days) than placebo (43.3 ± 5.3 days; P < .05). This difference strengthened when deaths were excluded and hospital stay was indexed to burn size (1.24 ± 0.15 days/{\%} TBSA burned vs 0.87 ± 0.05 days/{\%} TBSA burned, P < .05). We conclude that treatment using oxandrolone should be considered for use in the severely burned while hepatic transaminases are monitored.",
author = "Steven Wolf and Edelman, {Linda S.} and Nathan Kemalyan and Lorraine Donison and James Cross and Marcia Underwood and Spence, {Robert J.} and Dene Noppenberger and Palmieri, {Tina L.} and Greenhalgh, {David G.} and Marybeth Lawless and David Voigt and Paul Edwards and Petra Warner and Richard Kagan and Susan Hatfield and James Jeng and Daria Crean and John Hunt and Gary Purdue and Agnes Burris and Bruce Cairns and Mary Kessler and Klein, {Robert L.} and Rose Baker and Charles Yowler and Wendy Tutulo and Kevin Foster and Daniel Caruso and Brian Hildebrand and Wesley Benjamin and Cynthia Villarreal and Sanford, {Arthur P.} and Jeffrey Saffle",
year = "2006",
month = "3",
day = "1",
doi = "10.1097/01.BCR.0000202620.55751.4F",
language = "English (US)",
volume = "27",
pages = "131--139",
journal = "Journal of Burn Care and Research",
issn = "1559-047X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effects of oxandrolone on outcome measures in the severely burned

T2 - A multicenter prospective randomized double-blind trial

AU - Wolf, Steven

AU - Edelman, Linda S.

AU - Kemalyan, Nathan

AU - Donison, Lorraine

AU - Cross, James

AU - Underwood, Marcia

AU - Spence, Robert J.

AU - Noppenberger, Dene

AU - Palmieri, Tina L.

AU - Greenhalgh, David G.

AU - Lawless, Marybeth

AU - Voigt, David

AU - Edwards, Paul

AU - Warner, Petra

AU - Kagan, Richard

AU - Hatfield, Susan

AU - Jeng, James

AU - Crean, Daria

AU - Hunt, John

AU - Purdue, Gary

AU - Burris, Agnes

AU - Cairns, Bruce

AU - Kessler, Mary

AU - Klein, Robert L.

AU - Baker, Rose

AU - Yowler, Charles

AU - Tutulo, Wendy

AU - Foster, Kevin

AU - Caruso, Daniel

AU - Hildebrand, Brian

AU - Benjamin, Wesley

AU - Villarreal, Cynthia

AU - Sanford, Arthur P.

AU - Saffle, Jeffrey

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Severe burns induce pathophysiologic problems, among them catabolism of lean mass, leading to protracted hospitalization and prolonged recovery. Oxandrolone is an anabolic agent shown to decrease lean mass catabolism and improve wound healing in the severely burned patients. We enrolled 81 adult subjects with burns 20% to 60% TBSA in a multicenter trial testing the effects of oxandrolone on length of hospital stay. Subjects were randomized between oxandrolone 10 mg every 12 hours or placebo. The study was stopped halfway through projected enrollment because of a significant difference between groups found on planned interim analysis. We found that length of stay was shorter in the oxandrolone group (31.6 ± 3.1 days) than placebo (43.3 ± 5.3 days; P < .05). This difference strengthened when deaths were excluded and hospital stay was indexed to burn size (1.24 ± 0.15 days/% TBSA burned vs 0.87 ± 0.05 days/% TBSA burned, P < .05). We conclude that treatment using oxandrolone should be considered for use in the severely burned while hepatic transaminases are monitored.

AB - Severe burns induce pathophysiologic problems, among them catabolism of lean mass, leading to protracted hospitalization and prolonged recovery. Oxandrolone is an anabolic agent shown to decrease lean mass catabolism and improve wound healing in the severely burned patients. We enrolled 81 adult subjects with burns 20% to 60% TBSA in a multicenter trial testing the effects of oxandrolone on length of hospital stay. Subjects were randomized between oxandrolone 10 mg every 12 hours or placebo. The study was stopped halfway through projected enrollment because of a significant difference between groups found on planned interim analysis. We found that length of stay was shorter in the oxandrolone group (31.6 ± 3.1 days) than placebo (43.3 ± 5.3 days; P < .05). This difference strengthened when deaths were excluded and hospital stay was indexed to burn size (1.24 ± 0.15 days/% TBSA burned vs 0.87 ± 0.05 days/% TBSA burned, P < .05). We conclude that treatment using oxandrolone should be considered for use in the severely burned while hepatic transaminases are monitored.

UR - http://www.scopus.com/inward/record.url?scp=33745368821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745368821&partnerID=8YFLogxK

U2 - 10.1097/01.BCR.0000202620.55751.4F

DO - 10.1097/01.BCR.0000202620.55751.4F

M3 - Article

C2 - 16566555

AN - SCOPUS:33745368821

VL - 27

SP - 131

EP - 139

JO - Journal of Burn Care and Research

JF - Journal of Burn Care and Research

SN - 1559-047X

IS - 2

ER -